Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 13/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | BRS3 | P32247 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14273893 | 0.85 | HDAC1 (0.51) | BDKRB1 | |
| SCHEMBL5783245 | 0.84 | BDKRB1 (0.68) | BDKRB1SLC6A3SLC6A4ACHE | |
| SCHEMBL5782458 | 0.83 | BDKRB1 (0.65) | BDKRB1SLC6A3SLC6A4CNR1 | |
| SCHEMBL8958523 | 0.81 | BDKRB1 (0.49) | BDKRB1ACHE | |
| SCHEMBL5924540 | 0.80 | SLC6A3 (0.47) | BDKRB1SLC6A3SLC6A4BRS3 | |
| SCHEMBL8958409 | 0.80 | BDKRB1 (0.48) | BDKRB1ACHE | |
| SCHEMBL2338182 | 0.79 | BDKRB1 (1.00) | BDKRB1SLC6A3SLC6A4BRS3ACHE | |
| SCHEMBL3109493 | 0.79 | BDKRB1 (0.61) | BDKRB1SLC6A3SLC6A4ACHE | |
| SCHEMBL19033759 | 0.79 | CYP2C19 (0.54) | — | |
| SCHEMBL4400570 | 0.78 | CTSB (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091380-B2 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1476419-B1 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | MERCK & CO INC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050085667-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | MERCK SHARP & DOHME LLC | 2005-04-21 | — | — | US | disclosed |
| EP-1476419-A4 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | MERCK & CO INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1476419-A2 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003065789-A2 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085667-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, LTB4R2 | BDKRB1 1/4885SLC6A3 3890/4885SLC6A4 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.